Sepsis and septic shock are leading causes of morbidity and mortality among hospitalized patients. Sepsis and Septic Shock is a new study from Decision Resources, Inc., that examines how the need to reduce the incidence of, and mortality from sepsis has created a sales opportunity for sepsis therapeutics in the billions of dollars.
(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION ) High Risks, Great Rewards for Drug Developers
Sepsis and septic shock have been notoriously difficult indications for drug development. However, considering the high incidence of sepsis, high mortality, and vast unmet needs (there are currently no therapies available to directly treat the syndrome), this indication offers considerable market opportunity for pharmaceutical and biotechnology manufacturers able to develop effective therapies.
Novel Therapies Targeting the Inflammatory and Coagulation Cascade Have Significant Commercial Potential
A deeper understanding of the complex interplay between inflammation, coagulation, and fibrinolysis and their respective roles in the pathophysiology of sepsis has resulted in a wider search for new drug targets. Novel therapies for agents with anticoagulant and anti-inflammatory properties are currently in development and provide the promise of safe and effective treatments for sepsis. Among those evaluated in this study, experts in all of the seven major markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) are particularly enthusiastic about Eli Lilly's recombinant human activated protein C (rhAPC; Xigris) and indicate that this agent is likely to be the first market entry as an immunomodulator that directly targets the pathophysiology of septic shock. Results from rhAPC trials provide proof of concept that ameliorating homeostatic abnormalities that occur in sepsis can halt the progression of the syndrome and improve survival. If the efficacy and safety shown in Phase III trials hold up in the wider clinical setting, Xigris will create a paradigm shift in the treatment of severe sepsis and septic shock-opening the door for a host of additional promising therapies in development that directly target the inflammatory or coagulation cascade.
Sepsis and Septic Shock is part of Infectious Disease, one of six Pharmacor services that evaluate the commercial potential of drugs in research and development.
Decision Resources, Inc., is a world leader in pharmaceutical research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years. Visit the Decision Resources Web site at http://www.dresources.com/.
Contact: Frank Sama, 781.296.2553 (telephone), 781.296.2525 (fax), or email@example.com.
In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or firstname.lastname@example.org.
In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or email@example.com.
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840
SOURCE: Decision Resources, Inc.
Contact: Frank Sama of Decision Resources, Inc., +1-781-296-2553,